Embodiments are directed to a fascial elevator tool configured to protect a medical professional's fingers while an incision is made, the tool including a fascial elevator configured to separate layers of tissue, a support arm connected to the fascial elevator, and a connector on the support arm, the connector, configured to connect to a surgical cutting tool.
A microwave passive sensor includes a microwave receiver, a low noise amplifier coupled to the microwave receiver, a mixer coupled to the low noise amplifier, and a baseband amplifier coupled to the mixer.
A61B 5/0507 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves using microwaves or terahertz waves
3.
SYSTEM AND METHOD FOR BEHAVIORAL ANALYSIS OF SUSPICIOUS EVENTS AND MALICIOUS APPLICATIONS IN COMPUTER SYSTEMS
A method, non-transitory computer readable medium and system comprising receiving, at a computer system, data capturing a run time behavior of a binary object, extracting, with the computer system, the data from the run time behavior of the binary object, mapping, with the computer system, the extracted data into one or more interactive visual representations of the run time behavior of the binary object comprising a scalar representation of process calls, dependencies among processes and executable files, or time dependencies between the processes and the executable files, and classifying, with the computer system, the binary object as malicious or benign.
Embodiments of the present disclosure pertain to a plant or seed that includes one or more altered JASMONATE-ZIM DOMAIN repressor (JAZ) genes. Additional embodiments of the present disclosure pertain to methods of altering one or more JAZ genes of a plant or seed by introducing one or more alterations to the one or more JAZ genes of the plant or seed. The altered plants and seeds of the present disclosure may exhibit one or more altered properties, such as jasmonic acid (JA) insensitivity, enhanced resistance to pathogens, enhanced resistance to insects, enhanced fiber yield, enhanced fiber quality, or combinations thereof.
The present invention includes a method and device for storing hydrogen comprising: providing a mixture of a catalyst comprising a metal and a silicon oxide or carbon in a solvent; introducing a hydrogen into the solvent; and ultrasonically irradiating the mixture such that the hydrogen attaches to the catalyst to form hydrogenated catalyst; adding a fullerene into the solvent; and ultrasonically irradiating the hydrogenated catalyst and the fullerenes under conditions in which the hydrogen transfers from the catalyst to form a hydrogenated fullerene.
C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia
C01B 3/36 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using oxygen or mixtures containing oxygen as gasifying agents
B01J 19/10 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing sonic or ultrasonic vibrations
6.
Intermediate Passive Wireless Loop Coil and Methods of Use Thereof
An intermediate passive wireless loop circuit includes one or more first loop coils, one or more second loop coils, and a set of interconnecting wires that series or parallel connect the one or more first loop coils to the one or more second loop coils such that the one or more first loop coils are separated from the one or more second loop coils by a distance.
H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
H02J 50/40 - Circuit arrangements or systems for wireless supply or distribution of electric power using two or more transmitting or receiving devices
H02J 50/50 - Circuit arrangements or systems for wireless supply or distribution of electric power using additional energy repeaters between transmitting devices and receiving devices
7.
METHODS AND SYSTEMS FOR EVALUATING FIBER QUALITIES
Embodiments pertain to methods of evaluating fiber quality by (1) receiving at least one in-line hologram image of the fiber; (2) reconstructing the in-line hologram image of the fiber into at least one three-dimensional image of the fiber that includes fiber-related data; and (3) correlating the fiber-related data to fiber quality. Such methods may also include: (4) adjusting fiber-related conditions; and (5) repeating steps 1-3 after the adjustment. Further embodiments pertain to systems for evaluating fiber quality in accordance with the aforementioned methods. Such systems may include a receiving area with a region for housing a fiber, a light source associated with the receiving area, a chamber associated with the light source and receiving area, a camera within the chamber, a processor in electrical communication with the camera, a storage device, an algorithm associated with the storage device and a graphical user interface (GUI) associated with the processor.
Devices, methods and systems for producing functional textiles and electrically conductive composites including for electro-thermal membrane distillation using a reduced graphene oxide (rGO) coated membrane. The method includes introducing a feed solution to a membrane distillation module including rGO-coated membranes. The methods also includes applying a controlled voltage to the rGO-coated membrane. The method also includes generating joule heating. The joule heating locally heats the feed solution. The method also includes adjusting the controlled voltage. The method also includes volatilizing the target elements. The method also includes, responsive to the volatizing of the target elements, separating the target elements from the feed solution. The methods and systems producing functional textiles usable for electrochemical distillation of complex mixtures and for healthcare applications based on antimicrobial activity.
C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
D06M 11/74 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbon or graphiteTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbidesTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with graphitic acids or their salts
D06M 16/00 - Biochemical treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, e.g. enzymatic
D06M 23/06 - Processes in which the treating agent is dispersed in a gas, e.g. aerosols
D06M 23/08 - Processes in which the treating agent is applied in powder or granular form
9.
BIOACTIVE COMPOUNDS WITH PESTICIDE ACTIVITIES DERIVED FROM AGED CULTURES OF GREEN MICROALGAE
Embodiments of the present disclosure pertain to a composition suitable for use in treating an agricultural material. In some embodiments, the composition includes a microalgae culture, an extract of the microalgae culture, compounds from the microalgae culture, or combinations thereof. Additional embodiments of the present disclosure pertain to methods of treating an agricultural material by applying a composition of the present disclosure to the agricultural material.
A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
C12N 1/12 - Unicellular algaeCulture media therefor
The present invention includes compositions and method of treating a textile with an antimicrobial agent, the method comprising contacting the textile with an antimicrobial agent that comprises a reactive dye, carboxylic acid, or crosslinking agent comprising an organo-selenium compound in a treatment solution.
Methods for optimization of liquid oil production by huff-n-puff in shale reservoirs to achieve an improved (and optimal) oil recovery factor. The process determines and utilizes the optimum huff and puff times, number of cycles and soaking time under practical operation and reservoir conditions. The huff time in the process is a period so long that the pressure near the wellbore reaches the set maximum injection pressure during the huff period. The puff time in the process is the time required for the pressure near the wellbore to reach the set minimum production pressure during the puff period. Soaking is typically not necessary during the huff-n-puff gas injection in shale oil reservoirs. The number of huff-n-puff cycles is determinable by the time in which the economic rate cut-off is reached.
Hollow glass microspheres (HGMS) with a controlled nanotopographical surface structure (NSHGMS) demonstrate improved isolation and recovery of cells and other biological particles such as bacteria from biological fluid. Such functionalized HGMS are formed by exposing a plurality of hollow glass microspheres to a layer by layer deposition cycle of charged polymeric nanofilms to form a plurality of coated hollow glass microspheres and functionally binding a plurality of biotinylated antibodies to the plurality of coated hollow glass microspheres. Application of these HGMS in related biological particle isolation methods does not require specialized lab equipment or an external power source, and thus, can be used for separation of targeted cells from blood or other fluid in a resource-limited environment.
The present disclosure describes a self-sprayer device for self-administering an animal product to an animal and providing environmental enrichment to the animal.
A system and method for estimating an adsorption equilibria for one or more gases from pure component adsorption isotherms includes providing one or more processors, a memory communicably coupled to the one or more processors and an output device communicably coupled to the one or more processors, calculating an adsorption of each gas on a constant monolayer adsorption surface is calculated using the one or more processors and the generalized Langmuir isotherm equations (24)-(26) or equation (27), providing the adsorption of each gas to the output device, and developing a chemical process or product is developed using the adsorption of each gas.
G01N 25/48 - Investigating or analysing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
G06F 17/11 - Complex mathematical operations for solving equations
A surgical training system, method, and apparatus comprise a biomaterial, a first clamp configured to engage the biomaterial and a second clamp configured to engage the biomaterial, at least one actuator operably connected to at least one of the first clamp and the second clamp wherein the at least one actuator is configured to impart tension in the biomaterial, and a patient body simulator arranged under the biomaterial.
The present invention includes a mutant DNase 1L3 having at least about a 95% identity with a nucleic acid sequence encoding the protein of SEQ ID NO: 2-8 for a mutant DNase 1L3 comprising at least one mutation for post-translational modification or attachment of a molecule to the mutant DNase 1L3 to increase the serum half-life of the mutant DNase 1L3, nucleic acids encoding the same, host cells, and methods of making the mutant DNase 1L3.
Methods and systems for pre-treatment of sludge and biosolids in preparation for electrochemical valorization is disclosed herein. Such methods can include selecting a sludge source; preparing a slurry, where the slurry comprises the sludge source and an electrolyte; adjusting a pH of the slurry, where the adjusting the pH of the slurry results in the slurry having an adjusted pH in a range between approximately 8 and 13; flowing the slurry through a first electrochemical cell, where the first electrochemical cell enables partial oxidation of the sludge via hydroxyl radicals; and flowing the partially oxidized slurry from the first electrochemical cell to a second electrochemical cell for selective conversion, where the second electrochemical cell includes an anode, a cathode, and a catalyst.
22) generation from Earth's subsurface, and extraction thereof. The methods include forming at least one well in contact with a source rock formation, wherein the at least one well is configured to allow the introduction of a fluid composition into the source rock formation, then introducing the fluid composition into the source rock formation. Thereafter, hydrogen gas production is stimulated from the source rock formation through a serpentinization process, and is subsequently extracted.
The present invention includes compositions and methods of treating CNS-related conditions, comprising: administering an effective amount of a compound that lowers the levels of one or more branched-chain amino acids (BCAAs) or metabolites thereof, or any pharmaceutically acceptable salt thereof, wherein the CNS-related conditions is selected from the group consisting of Alzheimer's disease and any related forms of dementia including vascular dementia, Lewy body dementia, frontotemporal dementia, Creutzfeldt-Jacob disease, Wernicke-Korsakoff disease, and Huntington's disease, Multiple sclerosis, Parkinson's disease, autism, Amyotrophic lateral sclerosis (ALS), Hereditary diffuse leukoencephalopathy with spheroids (HDLS) and epilepsy.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
Provided herein is a fusion protein, expression vector, nucleic acid, or method of making and using a first HLA-G monomer and a second HLA-G monomer connected by a linker peptide expressed as a single chain, and optionally, comprising a providence virus globulin domain to prevent or reduce neovascularization.
Methods and systems for electrocatalysis of municipal sludge and biosolids. Such methods (and systems thereof) include selecting a sludge source; preparing a slurry, where the slurry comprises the sludge source and an electrolyte; adjusting a pH of the slurry, where the adjusting the pH of the slurry results in the slurry having an adjusted pH in a range between approximately (8) and (14); flowing the slurry through an electrochemical cell, where the electrochemical cell includes an anode, a cathode, and a catalyst; applying a potential between the anode and the cathode, where applying the potential includes oscillating a cell voltage between the anode and the cathode at an oscillation frequency; resultant to the applying the potential, breaking down carbon bonds in the slurry with nitrogen and phosphorus; releasing inorganic nitrogen and inorganic phosphorus; and obtaining an electrolyzed sludge, where the electrolyzed sludge includes an electrolyzed solid comprising nitrogen and phosphorus.
A capillary-incorporated bioprinting system for rapid engineering of vascularized tissues, the system comprising a three-dimensional printing head, wherein the three-dimensional printing head is configured on a three-axis linear stage; a spinneret, wherein the spinneret is configured on a horizontal linear stage and the spinneret is affixed above the three-dimensional printing head; a UV light source, wherein the UV light source is operatively coupled to the three-dimensional printing head and the spinneret, and adjacent to the spinneret; and a pair of parallel bars, wherein the pair of parallel bars are configured to collect a plurality of electrospun aligned microtubes.
Embodiments pertain to a computer-implemented method of predicting muscle fatigue in a subject by: (1) receiving data related to muscle fatigue in a muscle of the subject; (2) feeding the data into an algorithm to predict the muscle fatigue; and (3) outputting the predicted muscle fatigue. The algorithm my include: (a) an active compartment (M_A) model representing individual motor units (MUs) generating force at full capacity, (b) a resting compartment (M_R) model representing inactive MUs capable of rapid activation into force production, (c) a centrally fatigued compartment (M_FC) model representing fatigued MUs due to a central mechanism dominant at zero or near-zero joint velocities, with rapid recovery, and (d) a peripherally fatigued compartment (M_FP) model representing fatigued MUs due to a peripheral mechanism dominant at higher velocities, with slow recovery. Further embodiments pertain to a computing device for predicting muscle fatigue in a subject in accordance with such methods.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
24.
NITRIC OXIDE MODIFIED ATMOSPHERE PACKAGING TO MAINTAIN BEEF COLOR
Embodiments of the present disclosure pertain to methods of packaging meat by associating the meat with a nitric oxide composition and a packaging unit. In some embodiments, the association of the meat with the nitric oxide composition and packaging unit includes: (1) placing the meat in the packaging unit; (2) flowing the composition into the packaging unit; and (3) sealing the packaging unit. Additional embodiments of the present disclosure pertain to packaging units that include meat and a nitric oxide composition. In some embodiments, the meat and the composition are sealed in the packaging unit.
Embodiments of the present disclosure pertain to methods of forming a co-crystallized composition by mixing a first molecule in a solid phase with a second molecule in a liquid phase to form a mixture, and then co-crystallizing the mixture to form the co-crystallized composition in the form of a crystalline solid. The mixing of the first and second molecules may occur through the utilization of mechanical force, such as milling. The co-crystallization of the first and second molecules may occur by adding a solvent to the mixture of the molecules and then evaporating the added solvent. The methods may also include a step of utilizing the co-crystallized composition as seed crystals to grow additional co-crystallized compositions. Further embodiments of the present disclosure pertain to the formed co-crystallized compositions.
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
26.
EQUINE ALLERGIC AIRWAY DIAGNOSIS AND ENVIRONMENTAL AIR AND ALLERGEN ASSESSMENT
A monitoring system for equine allergic airway diagnosis and environmental and air allergen assessment comprises a collection muzzle, a sensor in fluidic connection with the collection muzzle, an environmental sensor disposed in an environment proximate to the collection muzzle, and a chemical sensor disposed in the environment proximate to the collection muzzle.
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (USA)
Inventor
Abbruscato, Thomas J.
Nozohouri, Saideh
Zhang, Yon
Trippier, Paul
Kumari, Shikha
Karamyan, Vardan T.
Esfahani, Shiva Hadi
Jayaraman, Srinidhi
Maddeboina, Krishnaiah
Jonnalagadda, Shirisha
Abstract
Provided herein are novel compositions and methods for enhancing neurolysin activity comprising: a molecule of Formula I, II, III, or IV a salt, or enantiomer thereof:
A system and method for categorizing and assessing wells comprises: retrieving by one or more processors, a geologic seal penetration data, a geologic storage reservoir penetration data, an underground source of drinking water protection data, a geologic seal protection data and a geologic storage reservoir protection data for one or more wells from a database; categorizing by the one or more processors, the one or more wells as a well type based on the retrieved data; obtaining by the one or more processors, a status of the one or more wells from the database; assessing by the one or more processors, an action priority of the one or more wells based on the well type and the status; and providing by the one or more processors, the action priority of the one or more wells to one or more devices communicably coupled to the one or more processors.
E21B 41/00 - Equipment or details not covered by groups
E21B 33/13 - Methods or devices for cementing, for plugging holes, crevices or the like
E21B 43/16 - Enhanced recovery methods for obtaining hydrocarbons
E21B 47/117 - Detecting leaks, e.g. from tubing, by pressure testing
E21B 49/00 - Testing the nature of borehole wallsFormation testingMethods or apparatus for obtaining samples of soil or well fluids, specially adapted to earth drilling or wells
29.
VACUUM CALORIMETER COMPRISING AN OPEN SYSTEM DIFFERENTIAL CALORIMETER
An open calorimetry system is configured to measure heat flow from, and power out of or into, a working substance. The working substance can interact with the environment, allowing heat and mass to enter and leave. The embodiments are configured to measure power over five orders of magnitude from 100 μW to 50 W in a normal room temperature environment.
Embodiments of the present disclosure pertain to a method of assessing a disease in a subject by receiving a biological sample of the subject; detecting a single nucleotide polymorphism at codon 72 of the P53 protein (SNP) from the biological sample; and correlating the detected SNP to disease prognosis in the subject. Further embodiments pertain to methods of treating a subject by detecting an SNP from a biological sample of the subject and editing the detected SNP to treat or prevent a disease in the subject. Additional embodiments pertain to diagnostic tests and computing devices for assessing a disease in a subject in accordance with the methods of the present disclosure.
Disclosed is a system and method for a microdevice to separate blood cells based on differences in antigen expression. Specifically, cells of the same phenotype are separated based on whether or not they are activated during infection or resting. The device of the present disclosure takes a small sample of blood and provides differential cell counts that can be used to test for infection and inflammatory response. The device can be used to identify sepsis and other infections rapidly. By measuring differences in activated white cell counts such as neutrophils, the device of the present disclosure measures physiological response to infection in hospitalized patients recovering from burns, surgeries, etc.
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
32.
DELIGNIFICATION OF MATERIALS IN DEEP EUTECTIC SOLVENTS
Embodiments of the present disclosure pertain to methods of removing lignin from a material by associating the material with a deep eutectic solvent (DES) that includes at least one hydrogen bond acceptor (HBA) and at least one hydrogen bond donor (HBD). The methods of the present disclosure may also include one or more steps of heating the solvent-associated material, separating the material from the solvent, drying the material, washing the material, and/or processing the material. Additional embodiments of the present disclosure pertain to delignified materials that are formed in accordance with the methods of the present disclosure.
A method, system, and apparatus for improving wind harvest efficiency comprises: a wind turbine, a processor, and a computer-usable medium embodying computer code, said computer-usable medium being coupled to said processor, said computer code comprising non-transitory instruction media executable by said processor configured for: setting a desired location range of a wind wake with a controller, determining an error signal indicative of a difference between a currently measured cross-stream thrust component of wind and an optimal cross-stream thrust component of wind, adjusting a speed of a rotor associated with the wind turbine according to the error signal, and confining a real-time position of the wind wake to the desired location range of the wind wake.
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventor
Dou, Huanyu
Xu, Yan
Abstract
Embodiments of the present disclosure pertain to methods of assessing pain in a subject by receiving one or more measured levels of glycine receptors of the subject; and correlating differentially expressed levels of the glycine receptors to pain. The methods of the present disclosure may also include a step of implementing a treatment decision based on the assessment. In some embodiments, the methods of the present disclosure may be repeated after implementing the treatment decision. Additional embodiments of the present disclosure pertain to systems for assessing pain in a subject. In some embodiments, the systems include computer-readable storage mediums with program codes that implement the methods of the present disclosure.
Embodiments of the present disclosure pertain to methods of detecting hypoxemia in a subject by: (1) receiving a blood sample from the subject; (2) measuring the T2 relaxation time constant of the blood cell (e.g., blood cell pellet) of the blood sample (T2P value); and (3) correlating the measured T2P value to hypoxemia. In some embodiments, the methods of the present disclosure also include a step of correlating the measured T2P value to the subject's susceptibility to one or more hypoxemia-related conditions. Further embodiments of the present disclosure pertain to systems for detecting hypoxemia in a subject in accordance with the methods of the present disclosure.
Embodiments of the present disclosure pertain to methods of detecting hypoxemia in a subject by: (1) receiving a blood sample from the subject; (2) measuring the T2 relaxation time constant of the blood cell (e.g., blood cell pellet) of the blood sample (T2P value); and (3) correlating the measured T2P value to hypoxemia. In some embodiments, the methods of the present disclosure also include a step of correlating the measured T2P value to the subject's susceptibility to one or more hypoxemia-related conditions. Further embodiments of the present disclosure pertain to systems for detecting hypoxemia in a subject in accordance with the methods of the present disclosure.
A system includes a module configured to, for each footprint of a conveyor, identify vehicle groups having different vehicle characteristics and over-cycle distributions for each vehicle group or a back-to-back sequence of any given vehicle group by calculating, for each vehicle characteristic, over-cycle distributions for a first vehicle group having the vehicle characteristic and a second vehicle group not having the vehicle characteristic, determining whether either the number of vehicles in the first or second vehicle group or a difference between the over-cycle distributions for the first and second vehicle groups satisfies a threshold condition, and in response, cease identifying the vehicle groups. The module is configured to identify, for a received actual vehicle sequence, over-cycle risks based on the identified vehicle groups and the over-cycle distributions for each vehicle group or a back-to-back sequence of any given vehicle group. Other examples systems and methods are also disclosed.
A method for simulating conveyors includes receiving conveyor content for each cycle, the conveyor content including over-cycle distributions each specific to a vehicle group at a footprint of each conveyor for a footprint cycle time, determining a cumulative probability, for each footprint cycle time, across all of the footprints of the conveyor, of one or more of the footprints of the conveyor having that cycle time or less, and determining an individual probability, for each footprint cycle time, across all of the footprints of the conveyor, of the conveyor having that cycle time. The method further includes receiving a vehicle dispatch strategy and generating an alert indicating an over-cycle risk for the strategy based on the individual probabilities, and/or performing a discrete event simulation of the conveyors using one of the individual probabilities for each cycle and for each conveyor. Other examples systems and methods are also disclosed.
CSPP devices, methods of fabricating CSPP devices, and systems with CSPP devices are provided. The CSPP devices of this disclosure a polar dielectric substrate, an insulator layer disposed on the polar dielectric substrate. The polar dielectric substrate having a phonon polariton surface contacting the insulator layer. A grating including a plurality of grating structures is disposed on a plasmon polariton surface of the insulator layer such that adjacent grating structures of the plurality of grating structures form gaps therebetween. The insulator layer is exposed in each of the gaps and FP cavities are in the insulator layer under each of the grating structures, the FP cavities having a FP refractive index different than a refractive index of the regions of the insulator layer exposed by the gaps. The CSPP devices allow for phase modulation at longer infrared wavelengths and have a resonance due to the array of FP cavities.
G01N 21/3581 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared lightInvestigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using Terahertz radiation
G02F 1/21 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference
09 - Scientific and electric apparatus and instruments
Goods & Services
Downloadable software mobile apps for health and diet monitoring; downloadable educational mobile applications for personal development, health and nutrition; and downloadable software for educational services
41.
SEAMLESS MODE CHANGE BETWEEN GRID-CONNECTED MODE AND ISLANDED MODE FOR PV SYSTEMS
A unified control scheme to achieve seamless mode change between grid-connected mode and islanded mode for photovoltaic (PV) systems includes two decoupled control units: a DC-DC converter control unit and a DC-AC converter control unit. The DC-bus voltage is controlled through the DC-DC converter control unit, which supplies a “stiff DC source” to the DC-AC converter. The seamless mode change is implemented in the DC-AC converter control module via three digital switches between power flow control for grid-connected mode (or MPPT mode), and droop control for islanded mode (or droop mode), while preserving the continuity of control signals in all control units with the configurations of digital switches.
Provided herein are methods for the preparation of chitin nanocrystals, nanowhiskers, or both directly from a raw chitinous biomass without the prior isolation of a raw chitin polymer using an ionic liquid comprising: drying the raw chitinous biomass; and extracting in a single step a purified chitin by hydrolyzing with an ionic liquid from a raw, unpurified chitinous biomass, wherein the chitin nanocrystals and nanowhiskers comprise at least one of a high aspect ratio, are highly crystalline, or have high thermal stability.
A method for recovering target metal ions from a fluid stream using a chemically enhanced electrodialysis membrane, the method including selecting a cation-exchange membrane comprising a surface, synthesizing an ion sequestrant, wherein the ion sequestrant is capable of binding the target metal ions, grafting the ion sequestrant onto the cation-exchange membrane, wherein the grafting results in a thin layer of the ion sequestrant being affixed to the surface of the cation-exchange membrane, placing the cation-exchange membrane in an electrodialysis unit, wherein the electrodialysis unit comprises an anode, a cathode, and a diluate chamber, passing a diluate stream through the diluate chamber, wherein the diluate stream comprises the target metal ions, passing the diluate stream through the thin layer of the ion sequestrant affixed to the surface of the cation-exchange membrane, and binding the target metal ions to the cathode-exchange membrane.
C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 71/82 - Macromolecular material not specifically provided for in a single one of groups characterised by the presence of specified groups, e.g. introduced by chemical after-treatment
C02F 103/06 - Contaminated groundwater or leachate
C02F 103/10 - Nature of the water, waste water, sewage or sludge to be treated from quarries or from mining activities
C02F 103/36 - Nature of the water, waste water, sewage or sludge to be treated from the chemical industry not provided for in groups from the manufacture of organic compounds
44.
SONOCHEMICAL SYNTHESIS METHODS AND RELATED APPLICATIONS
B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
B01J 23/83 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with rare earths or actinides
C01B 3/38 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts
C01B 3/34 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents
45.
GFRA2 ANTIBODIES AND THEIR USE IN CANCER TREATMENT
Embodiments of the present disclosure pertain to an antibody that binds to GDNF family receptor alpha 2 (GFRA2), where the antibody may be in a modified form that includes, without limitation, a humanized form, a bispecific antibody, a chimeric form, a drug conjugated form, a bispecific form, an immunocytokine form, a labeled form, a fragmented form, or combinations thereof. Additional embodiments pertain to methods of treating or preventing a cancer in a subject by administering to the subject an antibody of the present disclosure. Further embodiments pertain to methods of diagnosing a subject with a GRFA2 positive cancer by exposing a specimen from the subject to an antibody of the present disclosure. Additional embodiments pertain to chimeric antigen receptor T-cells that express an antibody of the present disclosure and methods of treating or preventing a cancer in a subject by administering them to the subject.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Embodiments described herein provide for metal-insulator-metal (MIM) capacitors, supercapacitors of MIM capacitors, and a method of forming MIM capacitors and supercapacitors. The MIM capacitors and supercapacitors include a plurality of capacitors disposed over each other, each capacitor includes a first conductive layer disposed over a substrate, a dielectric layer disposed on the first conductive layer, and a second conductive layer disposed on the dielectric layer.
The present invention includes composition and methods for making and using a selenium-carrier conjugate for in vivo administration comprising: covalently attaching a selenium compound that reacts in vivo with naturally occurring reduced thiols and oxygen to produce superoxide, which can include a Fenton Complex that allows for a generation of hydroxyl radicals, and that wherein the selenium-carrier conjugate is stabilized against enzymatic degradation and clearance from the body and the synthetic targeting carrier binds target.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Provided herein are compositions and methods for making a guar-based composite material comprising: a guar gum comprising 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, or 50% weight to weight of the composite; a cellulose comprising 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, or 50% weight to weight of the composite; and optionally a plasticizer, wherein the composite has a higher flexibility and tensile strength than either the guar gum or cellulose alone
The present invention relates to a method and apparatus for passive collection of sperm having improved motility from a semen sample. The semen sample is contacted with on side of a porous barrier and a nutrient-containing media is contacted with the other side of the porous barrier. More robust sperm migrate from the semen sample through the porous barrier and are collected in a nutrient-containing media.
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational services, namely, providing courses of instruction at the university level, and arranging and conducting educational conferences and academic exhibitions in the field of university academics; entertainment services, namely, arranging and conducting athletic competitions, athletic tournaments, and athletic exhibitions; entertainment services, namely, arranging and conducting live performances by musical groups and music festivals for cultural or entertainment purposes
51.
NANOPARTICLE SIZE AND ELEMENTAL COMPOSITION CHARACTERIZATION
Embodiments of the present disclosure pertain to methods of identifying one or more characteristics of particles by (1) placing the particles on a surface; (2) exposing the particles to an ion to result in emissions from the particles; (3) measuring the emissions from the particles; (4) generating an emission profile from the measured emissions; and (5) correlating the generated emission profile to one or more characteristics of the particles
The present invention includes a method of activating, modulating, and/or anergizing an immune response by targeting the junctional epithelia in the gingival crevice.
A rammed earth brick forming system comprises a compaction assembly configured to accept earthen material for compaction, a sub-frame assembly, wherein the compaction assembly is mounted to the compaction assembly, and an extractor configured to transport a finished brick out of the compaction assembly.
B28B 3/04 - Producing shaped articles from the material by using pressesPresses specially adapted therefor wherein a ram exerts pressure on the material in a moulding spaceRam heads of special form with one ram per mould
54.
Method of Treating Cancer With Atpenin A5 Derviatives
The present invention includes molecules, composition, and methods for making and using a molecule having the formula:
The present invention includes molecules, composition, and methods for making and using a molecule having the formula:
The present invention includes molecules, composition, and methods for making and using a molecule having the formula:
wherein R′ is selected from H, methoxy, methoxymethyl, glycosyl, phosphoryl, alkylamine, polyethylene glycol (PEG), or deuterated; X is selected from OH, methoxy, methoxymethyl, O-methoxymethyl, carbonyl, or alcohol; Y is O; and R″ is selected from H, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, or dodecyl, that are saturated or unsaturated, PEG, or triphenylphosphate groups; optionally one or both MeO groups are deuterated; and N is N-oxide or N-alkyl.
SELECTIVE AND NON-SELECTIVE OPIOID RECEPTOR FUNCTIONAL ANTAGONISTS AND METHODS RELATED THERETO FOR TREATMENT OF ADDICTION, OPIOD DEPENDENCE, AND NEUROPATHIC PAIN
Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as addiction, alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, fibromyalgia, and combinations thereof. The compounds act by acting as selective antagonist to the kappa (κ) opioid receptor. Further, disclosed compounds are an analog compound that can act as an antagonist to one or more opioid receptors. When present, these compounds lead to the inhibition of conditions, providing increased performance over known treatments. The disclosed compounds also shows the ability to cross the blood-brain-barrier in a highly efficient manner. The disclosed compounds are shown to be effective in the nanomolar range.
Embodiments of the present disclosure pertain to computer-implemented methods of predicting an outcome of a cardiac procedure in a subject by (1) receiving a plurality of health-related data from the subject; (2) feeding the health-related data into a risk prediction model that integrates the health-related data and predicts one or more outcomes of the cardiac procedure; and (3) generating an output from the risk prediction model, where the output includes the predicted outcomes of the cardiac procedure. The methods of the present disclosure may also include a step of (4) recommending a treatment decision based on the predicted outcomes of the cardiac procedure. Additional embodiments of the present disclosure pertain to a computing device that is operable for predicting an outcome of a cardiac procedure in a subject.
The disclosed embodiments are directed to a guide system comprising a cradle configured to couple to a probe and a guide structure configured to couple to a limb of a patient, the guide structure comprising a fastening component and at least two strips configured to connect to the fastening component, wherein each of the at least two strips further comprises a guide track formed thereon, wherein the probe cradle is configured to travel along the at least two strips.
A method of treating a cancer in a patient includes obtaining a sample from the patient, using a C-circle assay to detect a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, and administering an effect amount of at least one of PRIMA-1 or APR-246 to the patient.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Embodiments of the present disclosure pertain to methods and systems for assessing a subject's vulnerability to developing at least one cardiometabolic-related condition. Such methods and systems generally include the following steps or instructions: (1) receiving a plurality of health-related data of the subject; (2) calculating a risk score from the plurality of health-related data; (3) correlating the risk score to the subject's vulnerability to the cardiometabolic-related condition; and (4) making a treatment decision based on the subject's vulnerability to the cardiometabolicrelated condition.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
60.
APPARATUS AND METHOD FOR COLLECTION OF SPERM SAMPLES
The present invention relates to a method and apparatus for passive collection of sperm having improved motility from a semen sample. The semen sample is contacted with on side of a porous barrier and a nutrient-containing media is contacted with the other side of the porous barrier. More robust sperm migrate from the semen sample through the porous barrier and are collected in a nutrient-containing media.
The disclosed embodiments are directed to an eVTOL aircraft comprising a fuselage, wings mounted to the fuselage, where the wings comprise an undercambered lower surface, and an array of ducted fans mounted to the undercambered lower surface, wherein each fan in the array of ducted fans further comprises a duct and a plurality of rotor blades, each of the plurality of rotor blades comprising a zero sweep leading edge and an elliptical trailing edge.
A nonlinear radar system includes a first antenna configured to generate and emit an incident signal having a first frequency, a transponder tag attached to an existing portable object, wherein the transponder tag includes an electromagnetic nonlinear element configured to be detected by the incident signal. Upon being detected by the incident signal, the transponder tag is configured to transmit a reflected return harmonic signal having a second frequency different from the first frequency, wherein the reflected return harmonic signal is an on-off keying (OOK) signal. A second antenna is configured to receive the reflected return harmonic signal having the second frequency. The transponder tag includes a conductive layer in electrical communication with the electromagnetic nonlinear element including a Schottky diode.
The disclosed embodiments are directed to helmet systems including a helmet shell, energy-absorbing suspension pads, and an adjustable retention system, further including fluorescent and retroreflective trim, ear covers, and a face shield or visor or both. The configuration can be configured to pass NFPA standard tests, which can include helmet shell impact and thermal tests, and penetration tests. In addition, the helmet can be designed to facilitate the integration of other ancillary accessories such as communication and lighting systems.
A system for training detection dogs comprising a central computer; a plurality of olfactometers operably connected to the central computer, each olfactometer comprising one or more sampling ports; a plurality of odor channels in fluid communication with the sampling port; an independent controller operably coupled to the plurality of odor channels; and one or more sensors connected to the one or more sampling port; a cover disposed to the one or more covers and uncover one or more of the one or more sampling ports; a cover controller operably coupled to the one or more covers; and a feeder operably coupled to the cover controller.
The present invention includes composition and methods of delivering one or more nutrients to a subject comprising: delivering an effective amount of one or more nutrients into a gingival crevice wherein the amount is sufficient to supplement the diet of the subject for the nutrients.
09 - Scientific and electric apparatus and instruments
39 - Transport, packaging, storage and travel services
Goods & Services
Downloadable electronic files in the nature of school yearbook materials, namely, data, text and images; electronic publications, namely, school yearbooks, recorded on computer media; downloadable electronic files in the nature of articles, digital data, text and images in the field of historical preservation. Electronic storage of digital data, text and images
67.
LISTERIA MONOCYTOGENES AS A VECTOR FOR TUMOR-SPECIFIC DELIVERY OF CHEMOTHERAPEUTIC AGENTS
Listeria monocytogenesListeria monocytogenes bacterium (Listeria) that is associated with at least one therapeutic agent. The therapeutic agent may be associated with a surface of the Listeria through a Listeria binding agent. The therapeutic agent may also be covalently associated with the surface of the Listeria through a cleavable linker that directly links the therapeutic agent to the surface of the Listeria. Additional embodiments of the present disclosure pertain to methods of delivering at least one therapeutic agent to a subject by administering to the subject a Listeria of the present disclosure. Further embodiments of the present disclosure pertain to methods of making a Listeria of the present disclosure by associating the Listeria with at least one therapeutic agent.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Embodiments of the present disclosure pertain to methods of treating or preventing a condition in a subject by administering to the subject a composition having alpha-methyl-L-tryptophan. In additional embodiments, the method further includes a step of instructing the subject to administer the composition in order to treat or prevent the condition in the subject. In some embodiments, the condition includes, without limitation, hyperglycemia, diet-induced diabetes, high-fat diet-induced diabetes, insulin resistance, metabolic syndrome, extra weight, obesity, hepatic steatosis, and combinations thereof. Additional embodiments of the present disclosure pertain to compositions for use in treating or preventing a condition in a subject. In some embodiments, the composition includes alpha-methyl-L-tryptophan.
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Embodiments of the present disclosure pertain to a composition that is suitable for use in treating or preventing arterial stiffness in a subject. In some embodiments, the composition includes a recombinant human thioredoxin (rhTrx), derivatives thereof, peptide fragments thereof, mutants thereof, or combinations thereof. Additional embodiments of the present disclosure pertain to methods of treating or preventing arterial stiffness in a subject by administering the compositions of the present disclosure to the subject.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The disclosed embodiments are directed to a modular autonomous vehicle system comprising a blended wing body module, at least two high speed long range wing panel modules configured to interchangeably mount to the blended wing body module, at least two low speed high endurance wing panel modules configured to interchangeably mount to the blended wing body module, a vertical tails module configured to interchangeably mount to the blended wing body module, a vertical takeoff and landing fin module configured to interchangeably mount to the blended wing body module, a power train, and a wheels module with a plurality of wheels operably connected to the power train.
B60L 50/60 - Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells using power supplied by batteries
72.
CELL-LADEN BIOINK CIRCULATION-ASSISTED INKJET-BASED BIOPRINTING TO MITIGATE CELL SEDIMENTATION AND AGGREGATION
A system for active circulation of bioink in inkjet bioprinting, comprises a bioink reservoir, an inlet connected to a pump, an outlet from the pump to the bioink reservoir, wherein the pump circulates bioink from the inlet to the outlet.
A nonlinear radar system includes a handheld unit including a display screen, a first antenna configured to generate and emit an incident signal having a first frequency, and a second antenna configured to receive a reflected return harmonic signal having a second frequency, as well as a transponder tag is attached to an existing golf ball. Such a transponder tag is in communication with and responsive to the handheld unit, and includes an electromagnetic nonlinear element configured to be detected by the incident signal without the need for a line of sight. Upon being detected by the incident signal, the transponder tag is configured to transmit the reflected return harmonic signal having the second frequency different from the first frequency. The transponder tag is passive and does not require a power source other than incident radiation.
G01S 13/75 - Systems using reradiation of radio waves, e.g. secondary radar systemsAnalogous systems using transponders powered from received waves, e.g. using passive transponders
G01S 7/02 - Details of systems according to groups , , of systems according to group
G01S 7/03 - Details of HF subsystems specially adapted therefor, e.g. common to transmitter and receiver
G01S 13/88 - Radar or analogous systems, specially adapted for specific applications
G01S 13/00 - Systems using the reflection or reradiation of radio waves, e.g. radar systemsAnalogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
74.
MODIFIED PLANTS AND SEEDS WITH ENHANCED PHYSIOLOGICAL PERFORMANCE AND ENVIRONMENTAL STRESS RESISTANCE
Embodiments of the present disclosure pertain to methods of enhancing a physiological performance or environmental stress resistance of a plant or seed by exposing the plant or seed to a composition that includes ethanol, acetic acid, or combinations thereof. Additional embodiments of the present disclosure pertain to modified plants or seeds that demonstrate enhanced physiological performance, enhanced environmental stress resistance, or combinations thereof. In some embodiments, the modified plants or seeds are formed by exposing the plants or seeds to a composition of the present disclosure. In some embodiments, the enhanced physiological performance or environmental stress resistance may occur through inheritable epigenetic modifications in the plant or seed.
a hyperuniform-structured microchip is disclosed, which is capable of providing viable resolution of CTC subpopulations supporting the ability to determine whether there is a correlation between CTC heterogeneity and tumor progression.
Disclosed is a catheter tubing having surface expression of organo-selenium compositions capable of presenting anti-microbial properties on the surface of the catheter tubing which prevent microbial growth and the formation of biofilms. The disclosed compositions and methods support a wide variety of scenarios for catheter tubing applications, as organo-selenium can be stably incorporated into catheter tubing to inhibit bacterial attachment, growth, and biofilm formation for multiple uropathogenic organisms for long-term use with minimal to no leaching.
Provided herein is a method and system for detecting kinase activity, comprising: providing one or more mutated kinases, wherein the one or more mutated kinases comprise a mutation that enlarges an ATP binding pocket of the kinase; contacting the one or more mutated kinases with an ATP or ADP analog-nanoparticle conjugate capable of intracellular delivery of the ATP or
Provided herein is a method and system for detecting kinase activity, comprising: providing one or more mutated kinases, wherein the one or more mutated kinases comprise a mutation that enlarges an ATP binding pocket of the kinase; contacting the one or more mutated kinases with an ATP or ADP analog-nanoparticle conjugate capable of intracellular delivery of the ATP or
ADP analog-nanoparticle conjugate, wherein the ATP or ADP analog comprises a detectable label; assaying the one or more mutated kinases under conditions in which the ATP or ADP analog-nanoparticle conjugate contacts the one or more mutated kinases, wherein the one or more kinases react to transfer the detectable label to the substrate, wherein the ATP analog only fluoresces upon contact with the ATP binding pocket of the kinase.
A system and method of producing ammonia comprises reacting a nitrogen feed gas and a hydrogen feed gas in a reactor to form ammonia, wherein the reaction produces a reaction mixture comprising ammonia gas, unreacted nitrogen and unreacted hydrogen, absorbing the ammonia from the reaction mixture in an absorber column containing an absorber, the absorber comprising a support and a metal halide, outputting the ammonia absorbed by the absorber, and recycling the unreacted nitrogen and unreacted hydrogen.
Embodiments of the present disclosure pertain to methods of treating or preventing cancer in a subject by administering to the subject a composition that includes at least one of the compounds disclosed herein. The cancer to be treated or prevented can include, without limitation, lung cancer, breast cancer, cancers associated with an over-expression of a ral interacting protein, or combinations thereof. Further embodiments of the present disclosure pertain to the compositions of the present disclosure.
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
Embodiments of the present disclosure pertain to methods of treating or preventing a disorder in a subject by administering to the subject a composition that includes one or more of the following active components: a zinc finger protein ZPR1 (ZPR1), an analog thereof, a homolog thereof, a derivative thereof, or combinations thereof; an enhancer of expression of ZPR1, an analog thereof, a homolog thereof, or combinations thereof; nucleotides encoding ZPR1, an analog thereof, a homolog thereof, a derivative thereof, or combinations thereof; or combinations thereof. The disorder to be treated or prevented may be caused by at least one mutation in the Senataxin (SETX) gene, a downregulation of SETX protein levels, or may include a neurodegenerative disease or disorder. Further embodiments pertain to the aforementioned compositions, which may be suitable for use in treating or preventing one or more of the aforementioned disorders in a subject.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention includes a method and food product made by at least partially enclosing a food product with a water-permeable membrane; and contacting a brine or sugar solution with a water activity sufficiently high to draw water molecules across the water-permeable membrane and away from the food product to preserve the food.
A23L 13/77 - Tenderised or flavoured meat piecesMacerating or marinating solutions specially adapted therefor by mechanical treatment, e.g. kneading, rubbing or tumbling
A method and system for quantum exponentiation comprise a quantum circuit, the quantum circuit comprising a plurality of an integer number of d control qubits, an output register configured to store a current function value, at least one multiplication block, and an input register comprising a plurality of input qubits wherein successive multiplications are performed, according to the at least one multiplication block, between the current function value and successive constants stored in the input register, in order to evaluate a function.
A method, system, and apparatus for chromatography comprises a chromatographic system can include a column packed with mesoporous graphitized carbon (MGC). The MGC serves as an ideal stationary phase and facilitates the efficient isomeric separation of compounds such as permethylated glycans with unprecedented 10 mm long column. The column is anticipated to be an efficient and economical replacement for nanoflow PGC column which was phased out by the manufacturer due to poor performance and lack of reproducibility.
B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/22 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the construction of the column
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
Disclosed is a composition and method for a therapeutic treatment that is able to combat triple negative breast cancers (TNBCs). The class of urea compounds acts by blocking at inhibiting the mTOR signaling pathway, which, as a central regulator of mammalian metabolism and physiology that when inhibited leads to the induction of autophagocytosis. The disclosed compounds are further capable of reinitiating the p53 cycle as well as inhibition of the BNIP3/BNIP3L pathway. The disclosed compounds also shows the ability to cross the blood-brain-barrier where metastases can form. This new drug has the potential to be a powerful new treatment to combat invasive TNBCs.
C07C 275/30 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
THE METHODIST HOSPITAL (USA)
Inventor
Dhandayuthapani, Subramanian
Das, Kishore
Garniga, Omar A.
Jagannath, Chinnaswamy
Veerapandian, Raja
Abstract
Embodiments of the present disclosure pertains to a genetically altered bacterial strain that lacks functional versions of at least three of the following proteins: FbpA; SapM; Zmpl; DosR; FadD26; SigH; nuoG; and Eis. In some embodiments, the bacterial strain lacks functional versions of at least the following proteins: FbpA; SapM; Zmpl; and DosR. In some embodiments, the bacterial strain lacks functional versions of at least the following proteins: FbpA; SapM; Zmpl; DosR; FadD26; and SigH. In some embodiments, the bacterial strain lacks functional versions of at least the following proteins: SapM; Zmpl; and nuoG. Further embodiments of the present disclosure pertain to methods of treating or preventing a bacterial infection in a subject by administering to the subject a bacterial strain of the present disclosure. In some embodiments, the bacterial infection is tuberculosis.
Disclosed is a framework that performs interfacial spectroscopy for an interfacial wave characterization of a bubble-laden drop or similar interface-bound complex domains. The framework focuses on particle-laden droplets to be the representation of the plausible interface-bound systems. Accordingly, the impact of number, size and position of suspended solids on the frequency and decay spectra creating a coherently structured database can be determined, detected or otherwise identified and analyzed. Then, an inversion algorithm can be built so that the same particulate details can be extracted by comparing the experimentally recorded spectral data with the stored simulation results. Thirdly, the framework can perform experiments and/or analyses to check the effectiveness and accuracy of the entire detection process. Finally, the framework can provide a proof of uniqueness based on effective medium assumption that can be generalized for domains with discrete bodies to justify possible extension to more complex systems like living cells.
222 sensor; and a processor connected to each of the first and second sensors, and wherein the SIB system measures in real-time respiratory pressure and the inhalation and exhalation volumes of each breath of a patient.
Methods for optimization of liquid oil production by huff-n-puff in shale reservoirs to achieve an improved (and optimal) oil recovery factor. The process determines and utilizes the optimum huff and puff times, number of cycles and soaking time under practical operation and reservoir conditions. The huff time in the process is a period so long that the pressure near the wellbore reaches the set maximum injection pressure during the huff period. The puff time in the process is the time required for the pressure near the wellbore to reach the set minimum production pressure during the puff period. Soaking is typically not necessary during the huff-n-puff gas injection in shale oil reservoirs. The number of huff-n-puff cycles is determinable by the time in which the economic rate cut-off is reached.
Embodiments of the present disclosure pertain to methods of treating or preventing a neurological disorder in a subject by administering to the subject at least one microRNA (miRNA), at least one inhibitor of the miRNA, or combinations thereof. Additional embodiments of the present disclosure pertain to compositions that include at least one miRNA of the present disclosure, at least one inhibitor of the miRNAs of the present disclosure, or combinations thereof. In some embodiments, the composition is suitable for use in treating or preventing a neurological disorder in a subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A neutron detector for detecting neutrons with energies from meV to tens of MeV comprising one or more nitride (BN) strips electrically connected in parallel or series. In some embodiments, the two or more BN strips are stacked on one another. In other embodiments, the two or more BN strips are disposed on a substrate with a gap between the two or more BN strips.
The present invention includes a method of determining a prognosis of a subject with cancer, and treatments thereof, comprising: obtaining or having obtained a sample from the subject; and measuring in the sample a level of expression of one or more Complement or Complement related genes or proteins; and determining if the levels of expression of the Complement or Complement related gene or protein when compared to the levels of expression of the Complement or Complement related genes or proteins from a subject that does not have cancer, wherein a change in the level of expression of the Complement or Complement related genes or proteins is associated with an unfavorable prognosis or a favorable prognosis.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
92.
RECONSTRUCTION OF THE COTTON FIBER LENGTH DISTRIBUTION FROM A FIBROGRAM
Embodiments of the present disclosure pertain to computer-implemented methods of reconstructing a fiber length distribution of a fiber from its fibrogram by receiving the fibrogram; determining an end of the fibrogram; applying a windowed curve-fitting procedure to smoothen the fibrogram curve; and estimating the fiber length distribution of the fiber from the smoothened fibrogram curve. The methods may also include one or more steps of reconstructing an initial and missing portion of the fibrogram; assessing fiber quality based on the estimated fiber length distribution; adjusting one or more fiber-related conditions based on the estimated fiber length distribution; and repeating the method after the adjustment. Additional embodiments pertain to computing devices for reconstructing a fiber length distribution of a fiber from its fibrogram.
Embodiments of the present disclosure pertain to bioink compositions that are operational to form an artificial tissue. The bioink may include materials that are completely or primarily derived from humans, such as human tissues. Additional embodiments of the present disclosure pertain to artificial tissues that include a plurality of cells and a bioink of the present disclosure, where the bioink is embedded with the cells, and the artificial tissue is in the form of a three-dimensional structure. Further embodiments of the present disclosure pertain to methods of making the artificial tissues of the present disclosure by applying a plurality of cells and a bioink onto a surface.
Methods and systems for the electrochemical up-cycling of polymers. A slurry including a mixture of solid plastics flows through an electrochemical cell, which, through an applied potential, the plastics are converted into pure hydrogen, fuels, gasolines, and oxygen hydrogenated compounds that can be used for the synthesis of advanced materials and/or for easier biochemical/thermal degradation. Such methods and systems enables converting plastic waste to into fuels, chemicals, and high value products.
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
An open calorimetry system comprising an active vessel, a passive vessel, and a first and second heat flux detector in thermal communication with the active vessel and passive vessel respectively. A thermal reservoir is connected to the first heat flux detector and the second heat flux detector, wherein data from the heat flux detectors is used in a differential analysis resulting in an energy measurement of an article in the active vessel.
The present invention includes and immunogenic composition and methods of immunizing a mammal or avian comprising: a nanoparticle conjugated to one or more antigenic peptides or fusion polypeptides from more than one strain of virus, wherein the one or more antigenic peptides or fusion polypeptides elicit at least one of a humoral, T helper cell-1 (Th1), T helper cell-2 (Th2) or cytotoxic T cell (CTL) immune response. In certain embodiments the antigenic peptides or fusion polypeptides are selected from at least one of SEQ IN NOS: 1 to 16, 22 to 39, or any combination thereof.
A mechanically robust LIG membrane can be fabricated by directly lasing a poly(ether) sulfone (PES) membrane support, the PES membranes being formed through a NIPS technique treated with Glycerol to control the pore collapse upon drying, to create a graphene layer on the top and/or bottom of the PES membrane.
The present invention includes a method and method for preserving a fish or seafood product comprising: contacting an emulsion with a meat product for a time sufficient to, wherein the emulsion comprises by weight: 10% to 50% water, 0.1 to 4.0% Quillaja, 0.1% to 8% meat flavoring, 60% to 85% high oleic sunflower oil, meat seasoning, 0-2.0% salt; salt, and optionally adding one or more stabilizers; a first pasteurizing step; vacuum packing the fish or seafood in a moisture and oxygen-impermeable packaging film; a second pasteurizing step.
B65B 31/04 - Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
B65B 25/06 - Packaging slices or specially-shaped pieces of meat, cheese, or other plastic or tacky products
99.
System, method and apparatus for test kit for rapid viral diagnostic sensor
A kit for testing for a virus and interacting with a sensor are disclosed. For example, the kit can include a first container having a first media for conditioning, catalyst formation and rinsing of the sensor. The first media can comprise V mL of 1 M KOH. The kit can have a second container with a second media for negative control (baseline solution) for the sensor. The second media can comprise W ML of 0.01 M KOH. The kit can further include a third container having a third media for sample testing with the sensor. The third media can comprise X mL of 0.01 M KOH. The third container can receive Y mL of saliva to complete a Z mL total volume in the third container prior to sample testing. In some versions, a ratio V: W: X: Y: Z=1.0: 1.0: 0.9: 0.1: 1.0 can be used.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
The present invention includes compositions and methods of using a molecule of Formula I:
The present invention includes compositions and methods of using a molecule of Formula I:
The present invention includes compositions and methods of using a molecule of Formula I:
wherein R is selected from methyl, ethyl, propyl, isopropyl, butyl, phenyl, cyclohexyl, fluoro, chloro, methoxy, ethoxy, butoxy, phenoxy, aryl, alkene, alkyne, and heterocyclic. The molecule of Formula I is a ligand until a metal is added, at which time the molecule is a catalyst.
B01J 38/68 - Liquid treating or treating in liquid phase, e.g. dissolved or suspended including substantial dissolution or chemical precipitation of a catalyst component in the ultimate reconstitution of the catalyst
